Biocentury reported that three biotechs raised more than $850 million in upsized IPOs, supported by strong aftermarket trading. The slate includes follow-on activity driven by data readouts for companies such as Oruka and Veradermics, plus continuing financing momentum in the sector. Other capital signals included PIPE support for an in-licensing deal as Cue added a new CEO. Separately, Hemab Therapeutics priced an upsized IPO, lifting gross proceeds to $301.5 million for coagulation-disorder targets. Together, the reports underscore that 2026’s IPO window remains open for story-rich biotech assets with near-term clinical credibility.